New hope for advanced cancers with DNA repair flaws: PARP inhibitor trial opens

NCT ID NCT04550494

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 39 times

Summary

This study tests the drug talazoparib in adults with advanced solid tumors (like breast, prostate, ovarian, pancreatic, or stomach cancer) that have certain gene changes affecting DNA repair. The drug blocks a protein called PARP, which cancer cells need to fix their DNA, potentially causing them to die. The goal is to see if the drug can shrink tumors or slow their growth, and whether taking different PARP inhibitors one after another might help some patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • National Cancer Institute Developmental Therapeutics Clinic

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact

    Contact Phone: •••-•••-••••

  • National Institutes of Health Clinical Center

    ACTIVE_NOT_RECRUITING

    Bethesda, Maryland, 20892, United States

  • UF Health Cancer Institute - Gainesville

    RECRUITING

    Gainesville, Florida, 32610, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Oklahoma Health Sciences Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.